StockWireNews

This Approx. $.30 NYSE Stock Packs 1,233% Potential Upside To Analyst $4 Price Target (Multiple Key Catalysts)

Multiple Analysts Chime In - Several Key Catalysts

January 13th

Good Morning,

With multiple analysts chiming in on this new stock profile, it could be the next big breakout idea of 2020.

Your stock idea for Monday, January 13th is:

> Actinium Pharmaceuticals, Inc. (ATNM) <

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) is a publicly traded biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells both safely and effectively.

ATNM has many positives going for the company and several key catalysts that could see their stock's share price take off in 2020.

Here are the most important catalysts that you need to know:

ATNM Catalyst #1 - Multiple Analyst Reports/Price Targets

JonesTrading

“We have revised our estimates to reflect these timeline expectations, but remain firmly impressed with Iomab-B’s safety, feasibility, and early efficacy findings in SIERRA and optimistic about the trial’s odds of a positive conclusion. Having reached this key checkpoint, the next potential SIERRA- related catalyst is likely to be safety and feasibility data (akin to what was presented at ASH 2018 for the first 25% of patients in SIERRA) for the first 50% of patients now enrolled, which may be reported at ASH this December, if not sooner.

Additionally, we hope to see confirmation of the standout effects of Iomab-B alone on pre-transplant blast counts among the 75 patients currently enrolled (potentially in 1H:20) as a follow-up to what was seen in the first 38 patients at ASCO last month."

The company maintained their "BUY" rating and moved their 12-month price target to $4.00/share.

At a price target of $4.00, JonesTrading is giving ATNM upwards of an approximate 1,233% potential upside from the stock's approximate $.30 current trading level.

William Blair & Co.

Analyst Andy Hsieh said, “Actinium’s lead asset, Iomab-B, is an antibody-radiation conjugate composed of an anti-CD45 antibody that is linked to radioisotope iodine-131. The compound is being investigated as a conditioning regimen prior to hematopoietic stem cell transplantation in the acute myeloid leukemia, or AML, setting. Conditioning regimens are responsible for eliminating residual cancer cells, removing healthy cells in the bone marrow so that donor stem cells can reside and thrive, and reducing the host immune activity to prevent tissue rejection, thereby optimizing the outcome for transplantation.

Stem cell transplantation is the only treatment for AML that could lead to long-term remission; however, given the toxicity of conditioning regimens, the procedure is typically performed only on young and fit patients. Combining the ability to home in on a tumor-specific marker and the potency of radiotherapy, targeted conditioning, such as Iomab-B, could improve on the current standard-of-care conditioning regimens.

Based on our estimates, the targeted conditioning market is roughly $600Mn in the United States and Europe, and positive results could fuel material growth in its clinical usage. Actinium is also making progress on several pipeline initiatives that could provide investors with multiple shots on goal.”

Zacks Investment Research + Maxim Group

ATNM has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price objective for the company in a research report on November 20th, 2019.

Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Actinium Pharmaceuticals in a research report.

With a $1.50 price target, Maxim Group is giving ATNM upside potential of approximately 400% from its current approximate trading level of $.30.

-----

ATNM Catalyst #2 - Institutional Investing / Bullish Hedge Funds

At the end of the third quarter in 2019, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock. On the other hand, there were a total of 4 hedge funds with a bullish position in ATNM a year ago.

More specifically, Sabby Capital was the largest shareholder of Actinium Pharmaceuticals Inc, with a stake worth $2Mn reported as of the end of September. Trailing Sabby Capital was Sio Capital, which amassed a stake valued at $1.4Mn. Endurant Capital Management, Renaissance Technologies, and Citadel Investment Group were also very fond of the stock, becoming one of the largest hedge fund holders of the company.

In terms of the portfolio weights assigned to each position Sabby Capital allocated the biggest weight to Actinium Pharmaceuticals Inc, around 1.09% of its 13F portfolio. Sio Capital is also relatively very bullish on the stock, dishing out 0.44% of its 13F equity portfolio to ATNM.

Image from MarketBeat.com.

Knowing that institutional investors/hedge funds appear to be for the most part extremely favorable about ATNM's future, it could give traders added confidence that share price growth may be right around the corner.

-----

ATNM Catalyst #3 - Pivotal Phase 3 Clinical Trial

In a December press release, the company updated the public with new findings from its Phase 3 SIERRA trial:

- Clinical data predicts dose level, administration window beginning 6.1 days post infusion and potential outpatient use for the Iomab-ACT program that Actinium intends to advance into human clinical studies

- Iomab-ACT program is intended to provide a universal chemotherapy-free solution for lymphodepletion and conditioning prior to adoptive cell therapy such as CAR-T at low dose and gene therapy at higher doses

Dale Ludwig, Ph.D., Actinium's Chief Scientific Officer, said, "CAR-T, adoptive cell therapy, and gene therapy are revolutionary medical advances with great promise. However, despite the innovation in these technologies, they continue to rely on generic chemotherapies for the necessary pre-conditioning prior to their administration, which are non-targeted and toxic. We believe this restricts the true potential of these therapies by hindering their efficacy and durability while increasing toxicities such as cytokine release syndrome and neurotoxicity.

With a starting clinical dose and time to clearance defined and supported by clinical results from the SIERRA trial, we look forward to our next step of advancing this program into human clinical testing with a cell therapy while continuing to introduce the Iomab-ACT program to cell and gene therapy developers."

Read the full article here.

-----

More About Actinium Pharmaceuticals, Inc. (ATNM)

From the company website:

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) is a publicly traded biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells both safely and effectively.

Actinium's lead product candidate, Iomab-B, is licensed from the Fred Hutchinson Cancer Research Center and is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. We believe Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. We are currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Actinium is also developing Actimab-A, our lead alpha-particle drug candidate. Actimab-A is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies.

In addition, Actinium has expanded its alpha-particle approach to include newly created drug candidate Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial.

Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element actinium-225 that are directed at various blood-borne or solid cancers.

ATNM Investor Presentation

https://www.actiniumpharma.com/

-----

ATNM could come out firing this morning. Get it on your radar quickly. If there are updates, I'll send them as fast as possible.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)